In a recent study, the researchers suggested that targeting the circuits responsible for visual acuity may be necessary in achieving optimal recovery of visual function and could aid in the ...

International retina specialists converge to explore groundbreaking treatments, drug delivery systems, and surgical innovations at the Retina World Congress 2025. The Retina World Congress 2025, led ...

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

Gore recently launched its silicone-free GORE IMPROJECT Plunger for 0.5-mL pre-filled syringes for the delivery of ophthalmic drugs. W. L. Gore and associates (Gore) announced the launch of its ...

Retina specialist Jay Chhablani, MD, discusses 3D choroidal vessel segmentation, uncovering critical insights into macular degeneration, diabetic retinopathy, and potential systemic disease ...

The results of an investigation into iRORA identified a wide spectrum of fundus autofluorescence patterns that corresponded with iRORA lesions and that those patterns were associated with conversion ...

Dilsher S. Dhoot, MD discusses how newer anti-VEGF treatments, particularly aflibercept 8mg, can provide improved anatomic outcomes and extended treatment intervals for patients with neovascular AMD ...

Dilsher S. Dhoot, MD discusses how second-generation anti-VEGF agents like aflibercept 8mg and faricimab demonstrate significant efficacy in treating diabetic macular edema (DME), allowing for ...

Michael Singer, MD, presented 100-week results from the RESTORE trial and shares key takeaways from his presentation at this year's American Society of Retina Specialists (ASRS) meeting. Michael ...

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and healthcare institutions. The US Food ...

More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The trial is expected to close randomization in early December 2024. This ...

Scientists enhance eye imaging with AI, achieving high-resolution views of retinal cells, potentially revolutionizing disease detection and monitoring in clinics. The National Institutes of Health ...